Semaglutide and joint pain: what the evidence actually shows

What STEP 1 and the prescribing information actually record

The STEP 1 trial (a 68-week study of nearly 2,000 adults, published in the New England Journal of Medicine) was the pivotal study that underpinned Wegovy's UK licence. Its side-effect data are the most cited source on semaglutide's safety profile. The profile that emerged was dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation were the headline findings, particularly in the weeks following a dose increase. If you want a fuller picture of whether Wegovy makes your joints hurt, the trial data are a useful starting point, though joint pain did not appear in the common or very common categories.

That does not mean it never occurs. The NHS semaglutide medicines page lists the known side effects drawn from the summary of product characteristics, and musculoskeletal pain is acknowledged at the infrequent end of the reporting spectrum. A prescriber reviewing your symptoms would consider whether the timing fits a drug effect or points to something else entirely, a flare of an existing condition, a new injury, or a change in activity levels that often follows starting treatment.

A question our prescribers hear most weeks is: "My knees are worse since I started, is that the injection?" The honest answer is that it is rarely straightforward. The medicine, the weight loss, and any change in how active you have become can all arrive at the same time.

How weight loss itself changes the load your joints carry

Losing weight fairly quickly, which many people do in the early months of semaglutide treatment, changes the mechanical environment of your joints in ways that are not always immediately comfortable. Cartilage that has adapted to one loading pattern over years does not instantly recalibrate. Tendons and the muscles that stabilise the knee, hip and ankle can experience increased demand if you become more active, which is common once appetite settles and energy returns.

This is not a reason to avoid weight loss; the long-term evidence for reducing joint load through sustained weight reduction is clear. But in the shorter term some people notice increased aching, particularly in weight-bearing joints, before things improve. If you are thinking about how your treatment fits into your broader health picture, the weight loss treatment overview covers what to expect across the different phases of treatment.

Gout is also worth mentioning here. Rapid weight loss from any cause can temporarily raise uric acid levels and trigger a gout flare, particularly in people who have had gout before. If the joint pain is acute, hot, red and localised (especially in the big toe or ankle) that pattern is worth mentioning to a clinician promptly rather than attributing it to the medicine alone.

The anti-inflammatory question: promising but not yet settled

There is genuine scientific interest in whether GLP-1 receptor agonists like semaglutide have anti-inflammatory properties beyond their effect on appetite and blood sugar. Some early research in animal models and small human studies has suggested reduced inflammatory markers in certain tissues. Whether that translates to meaningful benefit for conditions like osteoarthritis or rheumatoid arthritis in clinical practice is still being studied, no regulatory body has approved semaglutide for a joint condition, and it would be wrong to present those signals as established fact.

What can be said is that the weight-loss effect itself has a well-evidenced anti-inflammatory dimension. Adipose tissue secretes inflammatory cytokines; reducing it tends to reduce systemic inflammation over time. For people whose joint pain is partly driven by obesity-related inflammation, that downstream benefit is plausible, but it is a medium-to-long term consideration, not an immediate one.

If you have a diagnosed inflammatory joint condition and are considering semaglutide, the right conversation is with both your rheumatologist and the prescribing clinician. There is useful context on how semaglutide is used in the UK for weight management on our semaglutide information page.

When to get medical help, and what to tell your prescriber

Most joint aching that coincides with starting semaglutide settles within a few weeks, especially if it is muscle soreness from increased activity or the mechanical adjustment of losing weight. Some straightforward guidance on what warrants prompt attention:

Get medical help the same day if joint pain is severe and sudden, if a joint is hot, swollen and red, if you have difficulty bearing weight, or if pain is accompanied by fever. These patterns suggest something that needs assessment independent of your semaglutide treatment, including the possibility of a gout flare, infection or injury.

Tell your prescriber at your next review if aching has persisted beyond a few weeks without obvious cause, if it is getting worse rather than settling, or if it is affecting your sleep or mobility. Do not adjust your dose yourself in response to pain, the titration schedule exists for good reasons and any change should go through your prescriber.

You can also report unexpected symptoms through the MHRA Yellow Card scheme, which helps build the post-market safety picture for medicines like Wegovy. Related symptoms (such as chest pain on semaglutide, gas and abdominal discomfort, or skin pain associated with Wegovy) each have their own evidence base and are covered separately.

If you are considering starting Wegovy and want to understand whether it is clinically suitable for you, start your free consultation with our prescribers, who review every case the same day.